FDA Clearance Tracker · P960007-S021
TRANSCYTE HUMAN FIBROBLAST-DERIVED TEMPORARY SKIN SUBSTITUTE
Last checked: Nov 20, 2026Latest source record: Sep 20, 2011 (this decision)Source: openFDAMethods & limitations
Decided
Sep 20, 2011
Approved
Time to decision
197 days
Received Mar 7, 2011. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P960007-S021
- Device name
- TRANSCYTE HUMAN FIBROBLAST-DERIVED TEMPORARY SKIN SUBSTITUTE
- Applicant
- Shire Regenerative Medicine
- Applicant location
- San Diego, CA
- Received
- Mar 7, 2011
- Decided
- Sep 20, 2011
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P960007
Device type
- Device type
- Dressing, wound and burn, interactive (MGR)
- Device class
- Class III
- Specialty
- General & Plastic SurgeryWound Care
FDA's approval statement
As written in FDA's record.
APPROVAL FOR CHANGING FROM THE USE OF FETAL BOVINE SERUM TO THE USE OF BOVINE CALF SERUM AS A MEDIA SUPPLEMENT FOR EXPANDING CELLS IN EXPANDED SURFACE ROLLER BOTTLES, I.E., THE CELL EXPANSION PROCESS.
Source documents
Other decisions for Shire Regenerative Medicine
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.